What's Happening?
Novartis is seeking a highly motivated contractor scientist for a position in East Hanover, NJ, focusing on molecular biology, genomic PCR, and cell engineering. This role is crucial for an innovative
cell-engineering effort aimed at developing renewable, genetically defined T-cell platforms for Cell & Gene Therapy and immuno-oncology applications. The successful candidate will possess a strong foundation in molecular biology, with particular emphasis on genomic PCR, molecular characterization of engineered cells, and hands-on cell-engineering workflows. Key responsibilities include culturing and maintaining primary T cells and mammalian cell lines, executing cell-engineering workflows such as viral transduction and gene editing, and performing genomic PCR assays for characterization. The position requires a Master's degree with relevant experience or a PhD in a related scientific discipline, along with at least two years of work experience.
Why It's Important?
This role at Novartis is significant for advancing Cell & Gene Therapy and immuno-oncology, critical areas in U.S. biomedical research and healthcare. The development of genetically defined T-cell platforms has the potential to revolutionize cancer treatment and other immune-related diseases, offering more targeted and effective therapies. By investing in specialized scientific talent, Novartis is contributing to the U.S.'s leadership in biotechnology and pharmaceutical innovation. The work involved, particularly in genomic PCR and cell engineering, is foundational for creating safe and efficacious cell-based therapies. Success in this area could lead to new drug approvals, improved patient outcomes, and a stronger competitive position for the U.S. in the global biopharmaceutical market. It also highlights the ongoing demand for highly skilled scientists in these cutting-edge fields.
What's Next?
The hired scientist will contribute to the development of engineered T-cell populations, supporting targeted-integration and genome-engineering studies. Their work will involve clone screening, expansion, selection, banking, and characterization of engineered cell lines. The role also entails documenting workflows, analyzing data, and collaborating with interdisciplinary teams across Cell & Gene Therapy, Analytical Development, Bioanalytics, Process Development, and Research. The outcomes of this research are expected to contribute to project milestones and scientific decisions within Novartis, potentially leading to the advancement of new therapeutic candidates into clinical trials. The continuous refinement of these cell-engineering techniques will be crucial for the future success of cell and gene therapies.
Beyond the Headlines
The focus on renewable, genetically defined T-cell platforms represents a long-term vision for scalable and consistent cell therapies. This addresses a major challenge in current cell therapy manufacturing, which often relies on patient-specific cells that are difficult to produce consistently. The ability to engineer and characterize these cells precisely could lead to 'off-the-shelf' cell therapies, making them more accessible and affordable for a wider patient population. This shift could democratize advanced treatments and significantly impact healthcare economics. Furthermore, the ethical considerations surrounding gene editing and the creation of genetically modified cells will continue to be a prominent discussion point, requiring careful regulatory oversight and public engagement as these technologies progress from research to widespread clinical application.







